High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
about
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancerVariation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapyThe ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityEBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.
P2860
Q28391646-19DD52CF-76E8-464E-AB1F-B20403E67029Q28534042-729C8CF8-8B68-4259-938C-796F3514ADF4Q34676948-8FC1DFD5-E65B-4629-9AEC-83D03FAE8510Q35035831-771680E0-1367-45DE-B414-0EBC681F1CFDQ35510634-8F3FBA20-36B5-4C80-AE82-658101098C48Q36563172-B3BFDB3D-7C26-4DFB-A627-188ECB00AA12Q37706182-281C04A2-1C4D-4B15-8533-6CB435C4C65FQ38953629-6AD0A51F-DCCD-4699-9B7E-7AA1D821B75FQ43680067-F98C76C1-93DA-423B-8D6A-6E52C4888269Q46063656-D01B8A15-ADDF-49B7-BE31-75FE16CE1FCDQ47110861-F7A498BC-3DBF-414C-981C-63B32FDCFC97Q50936062-9BC4480D-5F77-4777-B5D4-79C1CF3DC4AAQ54310972-FD78E20A-C53E-4185-AF24-8E784A0AEB16Q54374136-0D9DE123-C6CC-4006-9317-31D170229F36
P2860
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
High-level mRNA of excision re ...... all cell lung cancer patients.
@en
High-level mRNA of excision re ...... all cell lung cancer patients.
@nl
type
label
High-level mRNA of excision re ...... all cell lung cancer patients.
@en
High-level mRNA of excision re ...... all cell lung cancer patients.
@nl
prefLabel
High-level mRNA of excision re ...... all cell lung cancer patients.
@en
High-level mRNA of excision re ...... all cell lung cancer patients.
@nl
P2093
P2860
P1433
P1476
High-level mRNA of excision re ...... all cell lung cancer patients.
@en
P2093
Caicun Zhou
Jianfang Xu
Ling Zhang
Shengxiang Ren
Songwen Zhou
P2860
P304
P356
10.3109/07357901003735659
P577
2010-05-26T00:00:00Z